Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

Table 2 Psychiatric hospitalizations 12 months before RLAT initiation for patients with ≥1 post-baseline visits (incidence density ratios)

Hospitalization status at baseline	US		Spain		Australia		Belgium
	All patients ^a	Patients not hospitalized at baseline	All patients ^a	Patients not hospitalized at baseline	All patients ^a	Patients not hospitalized at baseline	All patients ^a	Patients not hospitalized at baseline
Patients, n	435	413	1,339	1,220	734	354	393	173
Before baseline visit	0.63	0.59	0.45	0.37	1.34	0.82	1.05	0.49
Change (95% CI)^b	-0.35^c (-0.44 to -0.26)	-0.33^c (-0.42 to -0.24)	-0.29^c (-0.33 to -0.24)	-0.21^c (-0.25 to -0.17)	-0.62^c (-0.74 to -0.50)	-0.14 (-0.29 to 0.04)	-0.55^c (-0.67 to -0.44)	-0.11 (-0.26 to 0.03)
Percentage change	-55.6%	-55.9%	-64.4%	-56.8%	-46.3%	-17.1%	-52.4%	-22.4%

Patients had data for the post-baseline period up to the time of study discontinuation. Estimates for the pre-baseline and post-baseline periods may be based on different observation time periods within patients. Hospitalizations occurring before study start or after the last study visit were not included in the analysis.
^aFor patients who were hospitalized when initiating RLAT, the current hospitalization was considered as occurring before baseline.
^bConfidence intervals and P values were derived using the bootstrap resampling method.
^cP < 0.0001 for change in hospitalization.
CI = confidence interval; RLAT = risperidone long-acting therapy.

ISSN: 1744-859X